Merial La Polypropylene Syringe

Verify with FDA CVM →

84 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
84
Total Reports
4
Deaths Reported
480.0%
Death Rate

Active Ingredients

Merial La Polypropylene Syringe

Administration Routes

UnknownSubcutaneousUnassignedParenteralIntramuscular

Species Affected

Unknown 47
Cattle 35
Human 2

Most Affected Breeds

Unknown 49
Aberdeen Angus 14
Crossbred Bovine/Cattle 7
Cattle (other) 5
Cattle (unknown) 5
Beefmaster 3
Charolais 1

Most Reported Reactions

Stopper, abnormal 21
Uncoded sign 14
Lack of efficacy - NOS 12
Caps, Abnormal 8
Device Defective NOS 8
Systemic disorder NOS 8
Low weight gain 8
Lack of efficacy (endoparasite) - NOS 8
Scratching 6
Hair loss NOS 5
Poor coat condition 5
Death 5

Outcome Breakdown

Outcome Unknown
28 (75.7%)
Died
4 (10.8%)
Ongoing
4 (10.8%)
Recovered/Normal
1 (2.7%)

Data Summary

Metric Value
Total adverse event reports 84
Reports involving death 4
Case-fatality rate (reported events) 480.0%
Distinct species in reports 3
Distinct breeds in reports 7
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Merial La Polypropylene Syringe Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 84 adverse event reports referencing Merial La Polypropylene Syringe, including 4 reports in which the animal died — a 480.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Merial La Polypropylene Syringe. Reported administration routes include Unknown, Subcutaneous, Unassigned, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Merial La Polypropylene Syringe reports are Unknown (47 reports), Cattle (35 reports), Human (2 reports), with Unknown accounting for the largest share. Within those species, Unknown (49), Aberdeen Angus (14), Crossbred Bovine/Cattle (7) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Merial La Polypropylene Syringe are Stopper, abnormal (21), Uncoded sign (14), Lack of efficacy - NOS (12), Caps, Abnormal (8). Of the 37 reports with a coded outcome, Outcome Unknown is the leading category at 75.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Merial La Polypropylene Syringe.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial